197 related articles for article (PubMed ID: 14580776)
41. Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate.
Matsuda M; Morita Y; Shimada T; Miyatake J; Hirase C; Tanaka M; Tatsumi Y; Maeda Y; Kanamaru A
Int J Hematol; 2005 May; 81(4):307-9. PubMed ID: 15914360
[TBL] [Abstract][Full Text] [Related]
42. Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib.
Loriaux M; Deininger M
Leuk Lymphoma; 2004 Nov; 45(11):2197-203. PubMed ID: 15512807
[TBL] [Abstract][Full Text] [Related]
43. Philadelphia chromosome mosaicism at diagnosis in chronic myeloid leukemia: clinical correlates and effect on imatinib mesylate treatment outcome.
Landstrom AP; Knudson RA; Dewald GW; Ketterling RP; Tefferi A
Leuk Lymphoma; 2007 Nov; 48(11):2137-40. PubMed ID: 17926177
[TBL] [Abstract][Full Text] [Related]
44. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
Cortes JE; Talpaz M; Giles F; O'Brien S; Rios MB; Shan J; Garcia-Manero G; Faderl S; Thomas DA; Wierda W; Ferrajoli A; Jeha S; Kantarjian HM
Blood; 2003 May; 101(10):3794-800. PubMed ID: 12560227
[TBL] [Abstract][Full Text] [Related]
45. [Resistance to tumor specific therapy with imatinib by clonal selection of mutated cells].
Müller MC; Lahaye T; Hochhaus A
Dtsch Med Wochenschr; 2002 Oct; 127(42):2205-7. PubMed ID: 12397549
[TBL] [Abstract][Full Text] [Related]
46. Duplication of the Ph-chromosome as a possible mechanism of resistance to imatinib mesylate in patients with chronic myelogenous leukemia.
Ossard-Receveur A; Bernheim A; Clausse B; Danglot G; Fauvet D; Leon B; Lozach F; Bories D; Brouzes C; Bourhis JH; Turhan AG
Cancer Genet Cytogenet; 2005 Dec; 163(2):189-90. PubMed ID: 16337868
[No Abstract] [Full Text] [Related]
47. A novel t(6;7)(p24;q21) in a chronic myelocytic leukemia in complete cytogenetic remission after therapy with imatinib mesylate.
Gozzetti A; Tozzuoli D; Crupi R; Fanelli A; Gentili S; Bocchia M; Mazzotta S; Raspadori D; Lauria F
Cancer Genet Cytogenet; 2004 Jan; 148(2):152-4. PubMed ID: 14734229
[TBL] [Abstract][Full Text] [Related]
48. Prognostic factors associated with complete cytogenetic response in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
Cojbasić I; Macukanović-Golubović L
Srp Arh Celok Lek; 2010; 138(5-6):305-8. PubMed ID: 20607973
[TBL] [Abstract][Full Text] [Related]
49. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
50. Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of chronic myeloid leukemia patients to imatinib mesylate therapy.
Lippert E; Etienne G; Mozziconacci MJ; Laibe S; Gervais C; Girault S; Gachard N; Tigaud I; Dastugue N; Huguet F; Fort MP; Legros L; Eclache V; Mahon FX
Haematologica; 2010 Sep; 95(9):1604-7. PubMed ID: 20435623
[TBL] [Abstract][Full Text] [Related]
51. Philadelphia-negative acute myeloid leukemia with new chromosomal abnormalities developing after first-line imatinib treatment for chronic phase chronic myeloid leukemia.
Fava C; Cortes J
Am J Hematol; 2008 Sep; 83(9):755. PubMed ID: 18615551
[No Abstract] [Full Text] [Related]
52. Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy.
Rytting ME; Wierda WG
Leuk Lymphoma; 2004 Aug; 45(8):1623-6. PubMed ID: 15370215
[TBL] [Abstract][Full Text] [Related]
53. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
Hochhaus A; Kreil S; Corbin AS; La Rosée P; Müller MC; Lahaye T; Hanfstein B; Schoch C; Cross NC; Berger U; Gschaidmeier H; Druker BJ; Hehlmann R
Leukemia; 2002 Nov; 16(11):2190-6. PubMed ID: 12399961
[TBL] [Abstract][Full Text] [Related]
54. Hematologic and cytogenetic findings in eleven chronic myelogenous leukemia patients treated with imatinib mesylate at a tertiary care hospital.
Usman M; Kakepoto GN; Adil SN; Sajid R; Arain S; Khurshid M
J Pak Med Assoc; 2004 Jan; 54(1):17-20. PubMed ID: 15058636
[TBL] [Abstract][Full Text] [Related]
55. Detection of trisomy 8 in donor-derived Ph- cells in a patient with Ph+ chronic myeloid leukemia successfully treated with Imatinib (STI571) in relapse after allogeneic transplantation.
Agis H; Mannhalter C; Sperr WR; Keil F; Kalhs P; Pirc-Danoewinata H; Krauth MT; Haas OA; Geissler K; Lechner K; Valent P
Leuk Lymphoma; 2004 Jul; 45(7):1453-8. PubMed ID: 15359647
[TBL] [Abstract][Full Text] [Related]
56. Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: two cases with a different outcome.
Navarro JT; Feliu E; Grau J; Espinet B; Colomer D; Ribera JM; Oriol A; Granada I; Juncà J; Millá F
Am J Hematol; 2007 Sep; 82(9):849-51. PubMed ID: 17563075
[TBL] [Abstract][Full Text] [Related]
57. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
Walz C; Sattler M
Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
[TBL] [Abstract][Full Text] [Related]
58. Clinical implications of clonal chromosomal abnormalities in Philadelphia negative cells in CML patients after treated with tyrosine kinase inhibitors.
Ni H; Sun X; Xu Y; Lyle D; Petersen P; Zhao X; Drum H; You B; Liu D; Liu C; Jiang JG
Cancer Genet; 2019 Oct; 238():44-49. PubMed ID: 31425925
[TBL] [Abstract][Full Text] [Related]
59. Complete cytogenetic and molecular response to treatment with imatinib mesylate for philadelphia chromosome positive acute myeloid leukemia with multilineage dysplasia.
Ueda K; Horiike S; Zen K; Misawa S; Taniwaki M
Leuk Lymphoma; 2006 Sep; 47(9):1967-9. PubMed ID: 17065015
[No Abstract] [Full Text] [Related]
60. Clonal evolution with inv(11)(p15q22) and NUP98/DDX10 fusion gene in imatinib-resistant chronic myelogenous leukemia.
Yamamoto M; Kakihana K; Kurosu T; Murakami N; Miura O
Cancer Genet Cytogenet; 2005 Mar; 157(2):104-8. PubMed ID: 15721630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
